Category: Pharma & Biotech

Cannabis Science Announces Beta Launch of iCannabinoid, a High-Tech, State-of-the-Art, Medical Marijuana Social Media Educational Website

SHARE THIS POST Cannabis Science, Inc., (OTC: CBIS) a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the beta launch of iCannabinoid, the Company’s state-of-the-art, high technology social media and educational website. CBIS expects iCannabinoid to be the premier online platform for all things Cannabinoid-related, and will create a community of patients, advocates, doctors, researchers, parents, lawyers, growers, journalists, government and private-sector leaders, community organizers, and other interested parties. Join in our Beta Launch to connect, learn, and share; please visit our website and register at: http://icannabinoid.com/ iCannabinoid is designed to serve as an information center, resource hub, and support group for those seeking alternative cannabinoid treatments for various critical ailments such as Cancer, Arthritis, Parkinson’s Disease, Anxiety, Multiple Sclerosis, and more. This new website is designed to be a conduit to provide timely and relevant information for Cannabis users to share with each other 24/7 online.iCannabinoid My Health Modules are a significant feature in iCannabinoid that allows members to set up fully integrated personal health modules for tracking health records and set goals. Easy access and editable modules are provided for Members to create medication lists, monitor dosage results, monitor heart rate and blood pressure, check and track your sleep patterns, monitor pain influxes, along with the flexibility to create unique health tracking modules for your own personal needs. You can track your...

Read More

Lexaria and Neutrisci Enter Global Licensing Agreement

SHARE THIS POST Kelowna, British Columbia – February 26, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has entered an agreement with NeutriSci International Inc. (“NeutriSci”) (TSX-V: NU, OTCQB: NRXCF) such that NeutriSci now owns 100% of Ambarii Trade Corporation (“Ambarii”), and Lexaria has granted to NeutriSci an Intellectual Property License and Supply Agreement (the “License Agreement”) for the manufacturing and sale of CBD based products. Under the License Agreement, NeutriSci will continue the development and sales of its proprietary sublingual mouth-melt consumer products that incorporate Lexaria’s technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids in NeutriSci’s existing and pipeline product formats. Lexaria will earn ongoing royalty revenues from the sales generated by these products. “The relationship between our companies has evolved in a positive fashion and allows us each to focus on our core competencies which should benefit all stakeholders,” commented Chris Bunka, Lexaria CEO. “Neutrisci has developed a unique form factor that can now be empowered with Lexaria’s complementary technology which also allows consumers everywhere to benefit.” “We are very pleased to announce this long-term licensing and development agreement with Lexaria,” commented Glen Rehman, NeutriSci President. “This agreement will allow NeutriSci to focus on the global distribution of our proprietary CBD product line while letting Lexaria focus on licencing and development. This change...

Read More

India Globalization Advances Pre-Clinical Studies & CAM Products — CFN Media

SHARE THIS POST Seattle Washington, Feb. 26, 2018 (GLOBE NEWSWIRE) — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc’s (NYSE MKT: IGC) pursuit of numerous pre-clinical studies involving cannabinoids, while developing Complementary Alternative Medicines in the near-term to help patients and drive revenue. The cannabis industry has struggled with clinical trials due to the federal prohibition of cannabis and the difficulty in procuring cannabis plants for research. While the regulatory environment is showing signs of improvement, there are only a handful of companies that are pursuing rigorous clinical trials to prove the safety and efficacy of cannabinoids in treating underlying medical conditions. And, investors may want to take a closer look at these companies as they progress. Importance of Clinical Trials Clinical trials are research studies designed to explore if a medical strategy, treatment, or device is safe and effective for humans. By following strict scientific standards, clinical trials protect patients and help produce reliable study rather than relying on anecdotal evidence. The goal is to provide patients with higher quality medicine and protect them from unknown, unintended, or malicious side effects that may appear in unregulated drugs. Clinical trials are carried out in several different stages: • Phase I clinical trials are often healthy volunteers that are...

Read More

GB Sciences Receives Issuance of Its Cannabis Oil Production License

by Todd | Feb 21, 2018 | General, Pharma & Biotech | • GB Sciences enters full commercial operations with its cannabis oil production partners Cura Cannabis Solutions and RWH, a new venture co-founded by Deliciously Dee™ LAS VEGAS, Feb. 21, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) has been issued its production license and now begins full production operations in the Las Vegas, Nevada facility. Production license partners include Relax With Happy™ (“RWH”), a new venture co-founded by veteran cannabis chef, Deliciously Dee™, and Cura Cannabis Solutions, maker of the best-selling cannabis brand on the West Coast, Select Oil. Given already announced contractual arrangements with those production partners, operations are expected to generate significant monthly free cash flow after a ramp up period of approximately two months. John Poss, CEO & Chairman of the board of GB Sciences, said: “Partnering with the right companies is important to us. In any business, but perhaps particularly in this business, philosophical harmony between partners is what makes a partnership work, and work better. We are most fortunate to have Cura with its pristine reputation and demonstrated expertise, as well as Relax With Happy™, whose hand-crafted, micro-dosed edibles will vastly improve the options available in the Nevada market.” Cameron Forni, co-founder and president of Cura Cannabis Solutions remarked, “Quality, consistency and safety are three major priorities for us here at Cura,...

Read More

GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006

by Todd | Feb 21, 2018 | General, Pharma & Biotech | • Study did not meet its primary endpoint- • Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy- LONDON and CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint. GWP42006 is also being developed within the field of autism spectrum disorders (ASD) which will represent an increased therapeutic focus for ongoing development of this pipeline compound. GWP42006 trial in focal seizures The Phase 2a placebo-controlled study evaluated the efficacy and safety of GWP42006, which features cannabidivarin (CBDV) as the primary cannabinoid molecule, as add-on therapy in 162 adult patients with inadequately controlled focal seizures. The trial was conducted outside the United States, primarily in Eastern Europe. In the trial’s preliminary top-line results, both active and placebo arms showed similar reductions in focal seizures of approximately 40 percent. The extent of this placebo response is substantially greater than that seen in published studies of other treatments in similar patient...

Read More

Aphria Amends Arrangement Agreement with Nuuvera

by Todd | Feb 20, 2018 | CULTIVATION & RETAIL, Pharma & Biotech | LEAMINGTON, ON, Feb. 20, 2018 /CNW/ – Aphria Inc. (“Aphria” or the “Company”) (TSX: APH and US OTC: APHQF) announces today that it has entered into an amending agreement (the “Amendment”) to the previously announced arrangement agreement (the “Arrangement Agreement”) dated January 28, 2018 between Aphria and Nuuvera Inc. (‘Nuuvera”) whereby the Company and Nuuvera have agreed to amend the Arrangement Agreement to reduce both the required level of unrestricted cash and the consideration payable to holders of Nuuvera’s common shares (each a “Nuuvera Share”). The consideration under the Amendment has been reduced from $1.00 in cash plus 0.3546 of an Aphria common share (each an “Aphria Share”) for each Nuuvera Share to $0.60 in cash plus 0.3546 of an Aphria Share for each Nuuvera Share. Aphria had previously announced in connection with the Arrangement Agreement that it had secured irrevocable hard lock ups (the “Lock-Ups”) from Nuuvera shareholders (the “Lock Up Shareholders”) representing more than a majority of both the currently outstanding Nuuvera Shares and the “minority” Nuuvera shareholders to vote in favour of the Arrangement Agreement. In connection with the Amendment, Aphria has sought and received consent from Lock-Up Shareholders that, together with Nuuvera Shares already owned by Aphria, represent approximately 65% of the currently outstanding Nuuvera Shares and over 57% of the...

Read More